Green Thumb Industries (GTBIF) Cash from Investing Activities (2019 - 2026)
Green Thumb Industries (GTBIF) posted Cash from Investing Activities of -$20.6 million for Q1 2026, down 7.44% on a QoQ basis from -$19.2 million in Q4 2025, and up 32.69% year-over-year from -$15.5 million in Q1 2025.
Green Thumb Industries (GTBIF) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Green Thumb Industries' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$20.6 million for Q1 2026.
- Quarterly Cash from Investing Activities rose 32.69% year-over-year to -$20.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$120.4 million (down 9.61% YoY) and the FY2025 annual result came in at -$130.4 million, down 45.63% from the prior year.
- Cash from Investing Activities was -$20.6 million for Q1 2026 at Green Thumb Industries, down from -$19.2 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$10.3 million in Q1 2024 and bottomed at -$100.4 million in Q1 2022.
- A 5-year average of -$40.5 million and a median of -$36.1 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 1286.56% — and 2024, when it surged 84.65%.
- Green Thumb Industries' Cash from Investing Activities stood at -$58.8 million in 2022, then surged by 31.16% to -$40.5 million in 2023, then climbed by 10.78% to -$36.1 million in 2024, then surged by 46.95% to -$19.2 million in 2025, then retreated by 7.44% to -$20.6 million in 2026.
- Business Quant data shows GTBIF's Cash from Investing Activities at -$20.6 million in Q1 2026, -$19.2 million in Q4 2025, and -$13.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn | -20.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.58 Mn |
| Mar 31, 2026 | -20.58 Mn |
| Dec 31, 2025 | -19.15 Mn |
| Dec 31, 2025 | -19.15 Mn |
| Sep 30, 2025 | -13.00 Mn |
| Sep 30, 2025 | -13.00 Mn |
| Jun 30, 2025 | -67.67 Mn |
| Jun 30, 2025 | -67.67 Mn |
| Mar 31, 2025 | -30.57 Mn |
| Mar 31, 2025 | -30.57 Mn |
| Dec 31, 2024 | -36.10 Mn |
| Dec 31, 2024 | -36.10 Mn |
| Sep 30, 2024 | -19.11 Mn |
| Sep 30, 2024 | -19.11 Mn |
| Jun 30, 2024 | -24.06 Mn |
| Jun 30, 2024 | -24.06 Mn |
| Mar 31, 2024 | -10.27 Mn |
| Mar 31, 2024 | -10.27 Mn |
| Dec 31, 2023 | -40.46 Mn |
| Dec 31, 2023 | -40.46 Mn |